ACET Stock Forecast & Price Target

Adicet Bio is supported by prula-cel’s clinically meaningful efficacy in heavily pretreated LN/SLE patients, including 50% complete renal response and 54% DORIS remission at 12 months, with all responses remaining ongoing through 12 to 21 months and rapid, sustained improvements in SLEDAI-2K and PGA scores. The therapy’s immune-reset signal is reinforced by undetectable CD19+ B cells in all 22 efficacy-evaluable patients, naive-dominant B-cell reconstitution, and biomarker improvements in anti-dsDNA and complement, while safety remains differentiated with no Grade >2 CRS, no ICANS, no IEC-HS, and no GvHD across 24 patients. These data, combined with FDA alignment on a pivotal single-arm LN study, potential expansion into non-renal SLE, and the off-the-shelf allogeneic profile versus paused autologous competitors, underpin a constructive fundamental outlook.

Adicet Bio is exposed to substantial fundamental risk because its outlook depends on clinical and regulatory success for ADI-001, a program that may fail to demonstrate efficacy or could generate safety signals severe enough to halt development. The company also faces the possibility that its product candidates do not achieve projected sales estimates, which would weaken any future revenue base and extend reliance on external financing. In addition, ADI-001 could face commercial pressure from current and future therapies, limiting adoption even if development advances, and reinforcing a bearish view on the company’s long-term fundamentals.